The therapeutic focus of Тринальгин is centered on providing relief in clinical situations where pain is associated with symptoms of increased muscular activity and is generally associated with acute or disruptive episodes. The primary active ingredient is commonly used across domains where additional symptomatic support for severe pain and fever is needed.

This medication is applied in clinical settings requiring potent symptomatic support for moderate-to-severe acute pain. It is primarily relevant for conditions characterized by intense, cramping pain (colic) arising from the smooth muscles of the internal organs. This supports symptomatic management during acute episodes of renal colic, biliary colic, severe cramping linked to the gastrointestinal tract, and painful menstruation (dysmenorrhea). It is also utilized when a patient experiences this severe pain alongside a persistent high fever that has proven resistant to initial antipyretic measures.

The combination of actions assists with symptomatic management during difficult episodes by contributing to easing the overall symptom load when both pain and fever become more noticeable.

“The therapeutic benefit is relevant for easing symptoms related to heightened physiological activity, specifically intense pain and tension.”

Quick Fact: Relief for Acute Symptoms
Symptom Type: Spasmodic, Cramping, Colicky Pain
Severity: Moderate-to-Severe Acute Episodes
Key Benefit: Provides support that helps ease the overall symptom burden

Population Eligibility and Contraindications

The eligibility for using Trinalgin, a combination medicine containing Metamizole Sodium, is strictly defined by regulatory documentation. The product is generally permitted for use in adults and adolescents from 15 years of age or those weighing over 53 kg. However, use is prohibited or restricted in several key populations.

Classification	Population or Condition
Absolute Contraindication	History of Metamizole-induced agranulocytosis or other hematopoietic disorders.
Absolute Contraindication	Third trimester of pregnancy (risk of fetal renal and circulatory effects).
Absolute Contraindication	Infants below 3 months of age or 5 kg of body weight.
Absolute Contraindication	Patients with glaucoma, prostatic hypertrophy with urinary retention, or gastrointestinal obstruction.
Use Not Recommended	First and second trimesters of pregnancy or during breastfeeding.
Restricted Use	Patients with severe renal or hepatic impairment; multiple high doses should be avoided due to reduced elimination of metabolites.

Eligibility also requires caution in older adults, where dose reduction may be necessary due to prolonged clearance. The fixed-dose tablet formulation is not recommended for children under 15 years of age because the concentration is not suited for precise, weight-based pediatric dosing.

Interactions with other medicines and products

Regulatory information on Trinalgin interactions is primarily derived from the profile of its main active component, Metamizole Sodium. This component is a documented enzyme inducer of several Cytochrome P450 (CYP) enzymes, including CYP3A4, CYP2B6, and CYP2C19. This induction effect is expected to decrease the plasma concentrations and potentially reduce the effectiveness of co-administered medicines that are metabolized by these enzymes.

---

Documented Pharmacokinetic Interactions

The following substances have been explicitly noted in official regulatory documents as affected by Trinalgin's interaction profile:

• Immunosuppressants: Co-administration may reduce the blood levels of Cyclosporine and Tacrolimus.
• Other Agents: Expected to have decreased plasma concentrations include Bupropion, Efavirenz, and Methadone.

---

Documented Pharmacodynamic Interactions

Specific pharmacodynamic constraints are officially documented:

• Acetylsalicylic Acid (low-dose): Metamizole inhibits the specific anti-platelet effect, requiring caution if taken simultaneously.
• Neuroleptics: Co-administration with certain phenothiazine derivatives increases the risk of severe hypothermia.
• Glucocorticoids: Use with these agents is associated with an increased risk of gastro-intestinal bleeding.

Additionally, the consumption of alcohol must be avoided during treatment with this product.

Тринальгин is a combination pharmaceutical product. Its systemic pharmacodynamic effects are a superimposition of the mechanisms of its individual active components: Metamizole, Pitofenone, and Fenpiverinium bromide.

Metamizole acts primarily through its active metabolite, 4-methylaminoantipyrine (4-MAA), which functions as a non-selective inhibitor of the enzyme cyclooxygenase (COX), concentrating in the central nervous system (CNS). This inhibition modulates the enzymatic conversion of arachidonic acid to prostaglandins (PGs), reducing the production of these lipid mediators within the CNS. A downstream consequence is a central modulation of the neuronal sensitivity to nociceptive stimuli. Metamizole is also an agonist at certain opioidergic receptors and activates the endocannabinoid system, contributing to its overall central action.

Pitofenone exerts an anticholinergic effect, promoting relaxation of smooth muscle by inhibiting muscarinic acetylcholine receptors in peripheral tissues, which leads to a direct musculotropic effect. This action is complemented by Fenpiverinium bromide, a quaternary ammonium compound which functions as a peripheral muscarinic acetylcholine receptor antagonist, reinforcing the reduction of smooth muscle tone in the genitourinary and gastrointestinal tracts. The systemic physiological consequence is a decrease in excessive visceral smooth muscle contractility.

Тринальгин (Trinalgin) is a medication that contains the active substance Trimetazidine hydrochloride and is typically presented as a modified-release tablet for oral administration. It is essential to follow the specific instructions and dosage prescribed by your healthcare provider.

General Administration

• Oral Use: The tablets are to be swallowed whole with water. Do not crush, chew, or divide the tablets.
• With Meals: The medication is generally recommended to be taken twice daily—once in the morning and once in the evening—during meals. Taking the dose with food can aid absorption and is part of the established regimen.
• Dosage: The standard recommended dose is one 35 mg tablet taken two times per day.

---

Important Considerations

Patient Population	Recommended Use / Dosage
Standard Adult	One 35 mg modified-release tablet twice daily with meals.
Moderate Renal Impairment	In patients with creatinine clearance between 30 and 60 mL/min, the recommended dose is typically one 35 mg tablet once daily in the morning during breakfast.
Elderly Patients	Caution is advised due to potential age-related decrease in renal function. Dosage may need to be adjusted, particularly in cases of moderate renal impairment, following the guidance for that group.

---

Missed Dose

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and take only the next regularly scheduled dose. Do not double the dose to make up for a missed one. Adherence to the prescribed regimen is important for maintaining a stable concentration of the drug.

Тринальгин: Recent Clinical Evidence

Тринальгин is a fixed-dose combination product containing three active substances: Metamizole sodium, Pitofenone hydrochloride, and Fenpiverinium bromide. This combination is primarily studied for its potential effects in managing pain associated with spasms of smooth muscle, such as in various forms of colic (renal, biliary, intestinal) and spasms of the urinary tract.

---

Clinical Findings on the Components

Metamizole, the primary component (a pyrazolone derivative, also known as dipyrone), is recognized as a non-opioid analgesic and antipyretic agent with noted spasmolytic properties. Clinical studies and real-world evidence have shown its wide use for general pain, fever, and headache relief in various countries. Its analgesic action is often comparable to or greater than some other non-steroidal anti-inflammatory drugs (NSAIDs) in specific acute pain settings, such as post-operative pain.

Pitofenone is a spasmolytic agent with a direct relaxing effect on smooth muscle tissue. Studies on isolated human tissue preparations, such as those from the upper urinary tract, suggest it antagonizes both spontaneous and induced smooth muscle activity in a concentration-dependent manner.

Fenpiverinium bromide is an anticholinergic agent. Research indicates that its primary role is its parasympatholytic effect, which helps to relax smooth muscles via the blockade of acetylcholine receptors. In combination products, its effects on smooth muscle are observed to complement the action of pitofenone, particularly in conditions involving severe muscle spasm.

Component	Primary Observed Effect in Research
Metamizole	Analgesic and Antipyretic
Pitofenone	Direct Smooth Muscle Relaxant
Fenpiverinium	Anticholinergic/Spasmolytic

---

Safety Considerations

The use of combination products containing Metamizole is associated with a risk of agranulocytosis, a rare but potentially severe side effect characterized by a sharp drop in white blood cells. This risk is cited across numerous regulatory and clinical assessments worldwide, leading to the withdrawal or restriction of metamizole-containing products in many markets (e.g., the US, UK, and some EU countries). Real-world data collection in countries where the drug is still available assists in understanding the prevalence and risk factors associated with this adverse event.

Key Studies & References

1. Metamizole [Dipyrone] - LiverTox - NCBI Bookshelf (National Institutes of Health)
2. Pharmacogenetics of metamizole-induced agranulocytosis: a systematic review and drug regulation implications - Frontiers in Pharmacology

Common questions about Тринальгин (FAQ)

Q: How quickly should I expect Тринальгин to start providing relief?

The onset of action is generally described as rapid. Regulatory pharmacokinetic data indicates that the peak concentration of the active substance in the blood is typically reached within 1.4 to 2.0 hours after taking an oral dose. This time frame is when the maximum concentration of the drug is measured in the body.

---

Q: What is the typical duration of action for a single dose of Тринальгин?

The official instructions for the modified-release tablet formulation describe a dosing regimen of taking the medicine twice daily. The standard scheduling of taking the medicine twice daily aligns with the intended use for a consistent effect across a 24-hour period.

---

Q: Does Тринальгин contain caffeine or other stimulants?

According to the official product information, the active ingredients are Metamizole sodium, Pitofenone, and Fenpiverinium bromide. Caffeine or other stimulants are not listed as active components in the formulation.

---

Q: Are there any known foods or drinks that should be avoided when taking Тринальгин?

Official regulatory documents explicitly state that the consumption of alcohol must be avoided during treatment with this medication. While no specific foods are forbidden, the medicine is generally recommended to be taken with meals as part of the established regimen.

---

Q: Is there a risk of becoming dependent on Тринальгин over time?

The main component of the medicine is described in official texts as activating the opioidergic system within the body. However, the regulatory documentation does not classify or characterize this product as being habit-forming or having a known abuse risk.

---

Q: What is the classification of Тринальгин (prescription-only or available over-the-counter)?

The regulatory classification of this medicine, whether it is sold by prescription (Rx) or over-the-counter (OTC), varies significantly depending on the country or region. In some areas, it may be a prescription drug, while in others, it is withdrawn from the market or available without a prescription.

---

Q: Can Тринальгин be used to help with symptoms of a common cold?

The medicine is officially indicated for the management of pain associated with smooth muscle spasm. While one of its components is known to act as an antipyretic (fever reducer), it is not specifically indicated or approved for treating the complete syndrome of the common cold.

---

Q: Does using Тринальгин cause problems with driving or operating machinery?

Official safety listings for this medicine include adverse effects such as dizziness, headache, and blurred vision. Due to these potential effects, caution is advised when performing tasks that require mental alertness, such as driving or operating complex machinery.

---

Q: Is the chemical makeup of Тринальгин similar to that of other analgesics?

Regulatory information classifies the main component, Metamizole, as a pyrazolone derivative, which is a specific class of non-opioid analgesic. This central mechanism of action distinguishes it from peripheral non-steroidal anti-inflammatory drugs (NSAIDs).

---

Q: Are there different strengths of Тринальгин available?

Official product information indicates the medicine is available in two forms: a Tablet and a Solution for Injection. The availability of multiple presentations means different formulations and strengths are available for administration.

---

Q: What is the shelf life of Тринальгин?

Official instructions mandate that the medicine must not be used after the expiry date, which is printed on the packaging. This date specifies the defined period of stability for the product.

---

Q: Is it normal to feel a tingling sensation after taking Тринальгин?

A tingling sensation is not listed in the official documentation of known or reported common, uncommon, or rare side effects for this medication. Side effect listings are based on data collected and reported to regulatory health authorities.

---

Q: Can I use Тринальгин if I have a history of asthma?

For patients with a history of asthma or similar respiratory issues, clinical data associated with the main component, Metamizole, indicates a risk of intolerance reactions such as bronchospasm (a tightening of the airways).

---

Q: Is the packaging of Тринальгин child-resistant?

Official instructions mandate that the product must be stored and kept out of the sight and reach of children at all times. This is a general safety requirement, but the documentation does not specifically confirm the technical feature of child-resistant packaging.

---

Q: Is Тринальгин considered safe for long-term or repeated use?

Regulatory warnings note that the most critical, rare risk, Agranulocytosis, is explicitly not related to the dose or duration of exposure. Furthermore, official caution is advised for repeat high doses in patients with renal (kidney) or hepatic (liver) impairment.

---

Q: Are there any studies that have looked at how Тринальгин affects the liver?

Yes, the medicine's effect on the liver is monitored and documented by regulators. Official safety information notes that Acute Hepatic Failure (severe liver injury) is a severe adverse reaction that has been observed and reported to health authorities.

How to Store and Dispose of Trinalgin

Storage and disposal of Trinalgin (Metamizole/Pitofenone/Fenpiverinium Bromide) must strictly follow official governmental regulatory requirements to maintain product stability and ensure public safety.

Official Storage Conditions

Requirement	Official Instruction
Temperature	Store below 25, C (77°F).
Protection	Keep the product in the original container and protect from light and moisture.
Stability	Do not use the medicine after the expiry date printed on the packaging.
Safety	It is mandatory to keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Trinalgin must not be disposed of via wastewater (e.g., flushing) or household waste. Regulatory instructions require the medicine to be returned to a pharmacist or a recognized local collection point to ensure proper environmental handling of pharmaceutical waste.